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Abstract
Background: The VACTERL association (VACTERL) is the nonrandom
occurrence of at least three of these congenital anomalies: vertebral, anal, car-
diac, tracheoesophageal, renal, and limb anomalies. Despite suggestions for
involvement of several genes and nongenetic risk factors from small studies,
the etiology of VACTERL remains largely unknown.
Objective: To identify maternal risk factors for VACTERL in offspring in a
large European study.
Methods: A case–control study was performed using data from 28 EUROCAT
registries over the period 1997–2015 with case and control ascertainment
through hospital records, birth and death certificates, questionnaires, and/or
postmortem examinations. Cases were diagnosed with VACTERL, while con-
trols had a genetic syndrome and/or chromosomal abnormality. Data collected
included type of birth defect and maternal characteristics, such as age, use of
assisted reproductive techniques (ART), and chronic illnesses. Multivariable
logistic regression analyses were performed to estimate confounder adjusted
odds ratios (aOR) with 95% confidence intervals (95% CI).
Results: The study population consisted of 329 VACTERL cases and 49,724
controls with recognized syndromes or chromosomal abnormality. For couples
who conceived through ART, we found an increased risk of VACTERL (aOR
2.3 [95% CI 1.3, 3.9]) in offspring. Pregestational diabetes (aOR 3.1 [95% CI 1.1,
8.6]) and chronic lower obstructive pulmonary diseases (aOR 3.9 [95% CI 2.2,
6.7]) also increased the risk of having a child with VACTERL. Twin pregnan-
cies were not associated with VACTERL (aOR 0.6 [95% CI 0.3, 1.4]).
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Conclusion: We identified several maternal risk factors for VACTERL in off-
spring befitting a multifactorial etiology.
KEYWORD S
etiology, assisted reproductive techniques, maternal factors, pregestational diabetes, respiratory
disorders
1 | INTRODUCTION
The VACTERL association (VACTERL) is a very serious
condition that includes at least three of the following
congenital anomalies: vertebral, anorectal, cardiac,
tracheoesophageal fistula with or without esophageal atre-
sia (EA/TEF), renal, and limb anomalies (Solomon, 2011).
As no major genetic risk factors have been identified yet
and no genetic test is available, VACTERL is diagnosed by
excluding overlapping conditions that have multiple fea-
tures in common with VACTERL (Solomon, 2011). In most
patients, VACTERL occurs sporadically, but familial inheri-
tance and increased prevalence rates of component features
in first-degree relatives are observed (Hilger et al., 2012;
Reutter & Ludwig, 2013; Solomon, Pineda-Alvarez, Raam, &
Cummings, 2010). According to the data published by
EUROCAT, the European network for the surveillance of
congenital anomalies, the prevalence of VACTERL was 0.4
in 10.000 births in 2012–2017 (EUROCAT, 2019b). The
majority of VACTERL patients who survive the immediate
postnatal period undergo a series of complex surgical proce-
dures to restore normal organ function. The quality of life is
often reduced, as the patients frequently suffer from
sequelae, such as back pain resulting from vertebral anoma-
lies, incontinence or severe constipation as a result of an
anorectal malformation (ARM), dysphagia or gastroesopha-
geal reflux as a consequence of tracheoesophageal fistula
(TEF), and urinary tract infections due to renal anomalies
(Raam, Pineda-Alvarez, Hadley, & Solomon, 2011;
Wheeler & Weaver, 2005).
Until now, no major risk factors are known to be
involved in the etiology of VACTERL. The phenotypic het-
erogeneity among VACTERL patients is large (van de
Putte, van Rooij, et al., 2019), which makes etiologic
research into VACTERL difficult, as strong etiological het-
erogeneity is likely (Solomon, 2018). There is evidence that
a proportion of patients have a genetic basis, but other
than the suggestion of certain candidate genes based on
animal studies or case reports, no major genetic risk fac-
tors have been identified (Aguinaga, Zenteno, Perez-
Cano, & Moran, 2010; Garcia-Barcelo et al., 2008; Winberg
et al., 2014). Although it is certainly possible that genetic
risk factors are involved in the etiology of VACTERL,
maternal risk factors are hypothesized to play a role as
well (Solomon, 2018). For example, maternal diabetes and
assisted reproductive techniques (ART) were identified as
possible maternal risk factors. However, the evidence for
involvement of these factors in the etiology of VACTERL
is not strong, as it is mainly based on case reports (Castori,
Rinaldi, Capocaccia, Roggini, & Grammatico, 2008;
Kanasugi et al., 2013; Sunagawa et al., 2007) or studies
with very small sample sizes (Czeizel & Ludanyi, 1985;
van Rooij et al., 2010; Zwink et al., 2012).
In this study, we included the largest group of VACTERL
cases thus far described with the aim of identifying maternal
risk factors in the etiology of VACTERL in offspring.
2 | METHODS
2.1 | EUROCAT data collection
Standardized data from cases and controls were obtained
from the central database of JRC-EUROCAT, the
European network of population-based registries of con-
genital anomalies ("EUROCAT, 2019a). Registries report
cases annually to the Central Registry operated at
European Commission's the Joint Research Centre (JRC)
in Ispra, Italy (Kinsner-Ovaskainen et al., 2018; Tucker
et al., 2018). Hospital records, birth and death certificates,
maternal questionnaires, and postmortem examinations are
all used to ascertain the data in individual registries. In this
study, we used data from 28 full member EUROCAT regis-
tries from 15 European countries for the period between
1997 and 2015 (Figure 1). The International Classification
of Diseases (ICD) version 9 or 10 and the British Pediatric
Association (BPA) one digit extension were used to code all
congenital anomalies, syndromes, chromosomal abnormal-
ities, and maternal (chronic) illnesses. Data extraction was
completed for all registered cases by the JRC-EUROCAT
Central Registry in May 2018. All 28 participating registries
gave consent for their data to be extracted for this study.
2.2 | Case and control selection
The initial study population comprised 441 cases with the
VACTERL association and 50,165 controls with a genetic
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syndrome and/or chromosomal abnormality. Cases were
selected based on ICD-9-BPA codes 759895 and 75989,
ICD-10-BPA code Q8726, or OMIM/McKusick codes
192350, 314390, and 276950. Cases with an ICD-9-BPA
code 75989 were only selected when VATER/VACTERL
was specified in the text, as this ICD-BPA code is not spe-
cific for VATER/VACTERL. We included live births, fetal
deaths (miscarriages or stillbirths from 20 weeks gesta-
tion), and terminations of pregnancy for fetal anomaly
following prenatal diagnosis at any gestational age
(TOPFA). We excluded fetuses or infants with a diagnosis
of VACTERL with hydrocephalus (VACTERL-H), as this
is considered a separate condition with a suggested auto-
somal recessive or X-linked inheritance (OMIM %276950)
(n = 11). Cases with a syndrome that explains their phe-
notype, such as Fanconi anemia, caudal regression syn-
drome, Goldenhar syndrome, sirenomelia, and the 22q11
deletion syndrome were also excluded (n = 11).
The remaining 419 VACTERL cases were subdivided
into the three mutually exclusive VACTERL subtypes
introduced earlier: STRICT-VACTERL, VACTERL-LIKE,
and VACTERL-PLUS (van de Putte, van Rooij,
et al., 2019). The STRICT-VACTERL subtype contains
cases with ≥3 major VACTERL features. In the
VACTERL-LIKE subtype, we included cases with <3
major VACTERL features, but with additional minor
VACTERL features adding up to ≥3 major and minor
VACTERL features combined. The VACTERL-PLUS sub-
type includes all cases that fulfill either the STRICT-
VACTERL or the VACTERL-LIKE subtype criteria, but
have additional major congenital anomalies outside the
VACTERL spectrum. In addition, we introduced the NO-
VACTERL subgroup, containing patients originally diag-
nosed with VACTERL but actually not complying with
the diagnostic criteria (van de Putte, van Rooij,
et al., 2019). The NO-VACTERL cases (n = 80) and cases
for which the subtype was unknown due to missing
information on the individual anomalies (n = 10) were
excluded from further analyses. For some specific ana-
lyses, the numbers of cases and controls were lower
because some registries do not collect information on all
maternal risk factors in a systematic manner.
The control group included fetuses or infants with a
genetic syndrome or chromosomal abnormality, consisting
of live births, fetal deaths, and TOPFAs. We hypothesized
that these controls have a different etiology from
FIGURE 1 Map of the 28 participating EUROCAT registries with birth years covered and the total number of cases and controls that
were included in this study
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VACTERL cases, as genetic defects are minimally
influenced by maternal factors. Controls were selected
based on ICD-9-BPA codes: 75581, 75601, 75604,
7580–7583, 7585–7589, 7598, and 27910; and ICD-10-BPA
codes: Q4471, Q6190, Q7484, Q751, Q754, Q7581, Q87,
Q90-Q93, Q96-Q99, and D821. Frequently occurring syn-
dromes among the controls were trisomy 21 (46%), trisomy
18 (11%), Turner syndrome (5%), and trisomy 13 (4%).
2.3 | Exposure and outcomes
We included the following fetal/infant characteristics from
the EUROCAT registries: sex, birth year, birth type (live
birth, fetal deaths, TOPFA), survival (>1week of age),
birthweight (in grams), and gestational age (in completed
weeks). In addition, we included the following maternal
characteristics: age at birth (in years), multiple pregnancy
(vs. singleton pregnancy), the use of ART, including
in vitro fertilization (IVF), intracytoplasmatic sperm injec-
tion (ICSI), gamete intrafallopian transfer (GIFT), oocyte
donation, artificial insemination, or induced ovulation,
chronic illnesses with onset before pregnancy, and drugs
taken during the first trimester of pregnancy (from first
day of last menstrual period up to 12 weeks of gestation).
Parity and/or gravidity were not included as potential risk
factors in this study, as information on parity and gravidity
is not registered in a standardized way across the
EUROCAT registries.
Maternal age at birth was divided into <20, 20–34, and
≥35 years. For ART, we made a distinction based on the
invasiveness of the treatment: IVF, ICSI, GIFT, and egg
donation were considered invasive ARTs, whereas artifi-
cial insemination and ovulation induction were considered
noninvasive. Maternal illnesses included pregestational
diabetes (ICD-10 codes E10-E14, P701, O240, and O241;
ICD-9 codes 2500–2509, 7750, and 6480), chronic lower
obstructive pulmonary diseases (CLOPD) (ICD-10 codes
J40-J47; ICD-9 codes 490–496), and epilepsy (ICD-10
codes: G400-G409; ICD-9 codes 3450–3459).
2.4 | Statistical analysis
The statistical package IBM SPSS Statistics 25.0 (SPSS
Inc., Chicago, IL, USA) was used for the analysis. Using
logistic regression, we estimated crude odds ratios (ORs)
with 95% confidence intervals (95%CIs) for several poten-
tial risk factors for VACTERL, namely multiple preg-
nancy, ART, pregestational diabetes, CLOPD, and
epilepsy. In the multivariable analyses, the reporting reg-
istry was selected as a confounder a priori and was
included in all models. In addition, birth year, birth type,
and maternal age at birth were included as potential con-
founders, as well as the potential risk factors multiple
pregnancy, ART, pregestational diabetes, and CLOPD
that were not the primary factor of interest in the specific
analysis. All potential confounders were initially included
in the full model, from which they were subsequently
excluded when the OR did not change more than 10%
upon removal.
2.4.1 | Missing data
Registries were excluded from the analyses of specific risk
factors when they had >50% missing data for that factor.
As a result, the analyses regarding multiple pregnancy
were based on all 28 registries, the analyses regarding
ART on 16 registries, the analyses regarding
pregestational diabetes on 15 registries, and the analyses
regarding CLOPD and epilepsy on 14 registries. Within
those datasets for analysis, the percentages of missing
data varied from 0 to 23.8% for different variables. There-
fore, we performed all analyses on the determinants of
interest with multiple imputed data (50×) based on all
maternal and child characteristics and potential risk fac-
tors, as displayed in Tables 2 and 3 using SPSS for impu-
tation in addition to complete case analyses.
2.4.2 | Sensitivity analyses
Several sensitivity analyses were performed: (a) by using
multiple imputation (50×) to deal with the remaining
missing data after exclusion of registries with >50% miss-
ing data for specific analyses; (b) by inclusion of the NO-
VACTERL cases and cases with unknown subtype in the
case population; (c) by inclusion of additional mothers
with chronic illnesses based on information on drug use in
the first trimester (ATC codes: A10 for drugs used in dia-
betes, R03 for drugs used for obstructive airway diseases,
and N03 for antiepileptics); (d) by random exclusion of a
proportion of the controls with TOPFA to achieve similar
proportions of TOPFAs in the control group and the case
group; (e) by assuming that cases and controls with miss-
ing data on any of the potential risk factors were not
exposed to that factor; (f) by exclusion of controls with
imprinting disorders (Beckwith-Wiedemann syndrome,
Angelman syndrome, Silver-Russell syndrome, and
Prader-Willi syndrome) in the analyses regarding ART
and controls with caudal regression syndrome in the ana-
lyses for gestational diabetes because of the known associ-
ations of ART with imprinting disorders (Manipalviratn,
DeCherney, & Segars, 2009) and pregestational diabetes
with caudal regression syndrome (Garne et al., 2012).
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2.5 | Ethics approval
As we used anonymous data obtained from registries
with appropriate ethical approval, specific ethical com-
mittee approval was not required for this study.
3 | RESULTS
The 329 VACTERL cases were divided into 173 cases
(52%) belonging to the STRICT-VACTERL subtype,
71 cases (22%) belonging to the VACTERL-LIKE subtype,
and 85 cases (26%) belonging to the VACTERL-PLUS
subtype. Table 1 shows the percentages of the major
VACTERL component features as specified previously
(van de Putte, van Rooij, et al., 2019) among the cases in
this study. Further characteristics of our study population
are described in Table 2. The majority of the cases were
males (67%), whereas the proportions of males and
females in the control population were equal. The distri-
bution of birth years was quite similar for the case and
control group. The majority of the cases were live born
(76%), whereas this was 47% among the controls. On the
other hand, the percentage of TOPFA pregnancies was
49% among the controls, and 22% in the cases. The sur-
vival of live born children beyond the first week postpar-
tum was quite similar for cases and controls (88 vs. 96%),
while low birthweight and preterm birth were observed
approximately twice as often among the cases compared
TABLE 1 The proportions of major VACTERL component
features present in the 329 VACTERL cases included
N %
Vertebral anomalies 109 33.1
Anal anomalies 199 60.5
Cardiac anomalies 195 59.3
Tracheo-esophageal anomalies 200 60.8
Renal anomalies 164 49.8
Limb anomalies 81 24.6
Note: See van de Putte, van Rooij, et al. 2019 for the specification of
the congenital anomalies that belong to the major VACTERL com-
ponent features.
TABLE 2 Fetal/infant and maternal characteristics of VACTERL cases and controls
Missing data
Total number
cases/controls Cases N (%) Controls N (%)
Sex 7.2% 326/46,099
Male 217 (66.6) 23,136 (50.2)
Female 109 (33.4) 22,862 (49.6)
Indeterminate — 101 (0.2)
Year of birth or TOPFA 0% 329/49,724
1997–2000 39 (11.9) 6,273 (12.6)
2001–2005 71 (21.6) 11,128 (22.4)
2006–2010 113 (34.3) 16,557 (33.3)
2011–2015 106 (32.2) 15,766 (31.7)
Birth type 0.1% 329/49,697
Live birth 250 (76.0) 23,560 (47.4)
Stillbirth 5 (1.5) 1,668 (3.4)
TOPFA 74 (22.5) 24,469 (49.2)
Survival (>1 week postpartum)a 7.2% 246/21,860 217 (88.2) 20,892 (95.6)
Low birthweight (<2,500 g)a 11.0% 245/20,947 127 (51.8) 5,865 (28.0)
Preterm birth (<37 weeks)a 5.0% 248/22,360 111 (44.8) 4,885 (21.8)
Maternal age at birth 2.0% 327/48,727
<20 years 16 (4.9) 1,198 (2.5)
20–34 years 246 (75.2) 24,354 (50.0)
≥35 years 65 (19.9) 23,175 (47.5)
Notes: The numbers in this table are based on all 28 individual registries.
Abbreviation: TOPFA, terminations of pregnancy for fetal anomaly following prenatal diagnosis.
aOnly calculated for live births.
6 VAN DE PUTTE ET AL.
to controls (52 vs. 28% and 45 vs. 22%). Case mothers
were younger than the mothers of controls with a
genetic syndrome or chromosomal abnormality.
Among the cases, 20% had a mother aged ≥35 years at
birth, in comparison to 48% of the controls. Due to the
nature of our control population, the higher percentage
of TOPFA pregnancies and the higher maternal age
were expected.
In Table 3, the associations between the potential
maternal risk factors and VACTERL in offspring are
shown. Birth type, maternal age at birth, and ART proved
to be true confounders in some multivariable analyses.
Couples who conceived through ART had an increased
risk of having a child with VACTERL (aOR 2.3 [95% CI
1.3, 3.9]), with a slight difference in risk between invasive
and noninvasive techniques, such as artificial insemina-
tion or hormonal treatment (aOR 1.9 (95% CI 0.9, 4.0)
and aOR 2.8 (95% CI 1.3, 6.1), respectively). We observed
a more than threefold increased risk of VACTERL in off-
spring of mothers with pregestational diabetes (aOR 3.1
[95% CI 1.1, 8.6]) or CLOPD (aOR 3.9 [95% CI 2.2, 6.7]).
Cases seemed more likely to be delivered from a multiple
pregnancy (e.g., twin or triplet) compared to controls, but
adjustment for birth type and ART attenuated the aOR to
approximately the null value. Reliable ORs could not be
estimated for epilepsy, as fewer than three cases were
exposed to this maternal disorder. Due to small numbers
of exposed cases for most variables in the three VAC-
TERL subtypes, we were not able to estimate reliable
ORs for the subtypes.
In the sensitivity analyses using multiple imputation,
similar risk estimates were obtained for all variables com-
pared to the complete case analyses, except for the
adjusted OR for multiple pregnancy (aOR 1.4 [95% CI
0.8, 2.4]) instead of aOR 0.6 (95% CI 0.3, 1.4) (eTable 1).
As imputation did not change our interpretation of the
results, we performed the remaining sensitivity analyses
with the original data. In the sensitivity analyses with all
VACTERL cases originally selected, including the NO-
VACTERL cases and the VACTERL cases with unknown
subtype, similar risk estimates as those in Table 3 were
obtained as well, albeit marginally lower ORs for
pregestational diabetes and CLOPD (eTable 2). The
maternal chronic illnesses were mainly identified based
on the ICD-9 and ICD-10 codes for the specific diseases,
but a small percentage of mothers were identified based
on drug use only. When these mothers were included in
the analyses, the ORs for pregestational diabetes were
again marginally lower, whereas the ORs for CLOPD
were slightly higher (eTable 3). After equalizing the pro-
portions of TOPFAs among cases and controls by ran-
domly excluding 15,894 controls, similar results were
obtained as in the primary analysis (eTable 4). When we
assumed that all mothers with unknown exposure to a
specific risk factor were not exposed to that risk factor,
we observed similar risk estimates as shown in Table 3
for multiple pregnancy and ART, whereas the risk esti-
mates for pregestational diabetes and CLOPD were some-
what higher (eTable 5). Based on the ICD-10-BPA codes
Q8730, Q8785, Q8717, and Q8715 or on less specific codes
TABLE 3 Associations between maternal risk factors and the VACTERL association in offspring
Registries
included
Missing
data
Total cases/
controls
Cases
exposed
N (%)
Controls
exposed N (%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Multiple
pregnancy
28 1.3% 328/49,098 17 (5.2) 1,380 (2.8) 1.9 (1.2–3.1) 0.6 (0.3–1.4)a
ART 16 15.0% 147/18,092 15 (10.2) 888 (4.9) 2.2 (1.3–3.8) 2.3 (1.3–3.9)b
Noninvasive 16 15.3% 146/18,027 7 (4.8) 342 (1.9) 2.7 (1.2–5.7) 2.8 (1.3–6.1)b
Invasive 16 15.3% 146/18,027 7 (4.8) 481 (2.7) 1.9 (0.9–4.1) 1.9 (0.9–4.0)b
Pregestational
diabetes
15 22.6% 135/17,527 4 (3.0) 153 (0.9) 3.5 (1.3–9.5) 3.1 (1.1–8.6)c
CLOPD 14 23.8% 122/16,705 15 (12.3) 500 (3.0) 4.5 (2.6–7.9) 3.9 (2.2–6.7)d
Epilepsy 14 23.8% 122/16,705 2 (1.6) 84 (0.5) - -
Note: ORs were estimated if ≥3 cases were exposed. Registries with >50% missing data for a specific risk factor were excluded from the ana-
lyses for that factor.
Abbreviations: ART, assisted reproductive techniques; CI, confidence interval; CLOPD, chronic lower obstructive pulmonary disorders; OR,
odds ratio.
aAdjusted for reporting registry, ART, and birth type.
bAdjusted for reporting registry.
cAdjusted for reporting registry, maternal age, and birth type.
dAdjusted for reporting registry and birth type.
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in combination with a specification in the text, 264 con-
trols had imprinting disorders, while six controls had a
diagnosis of caudal regression syndrome. After exclusion
of these controls in the analyses for ART and
pregestational diabetes, respectively, the risk estimates
remained similar to those obtained in the primary analy-
sis (eTable 6).
4 | DISCUSSION
Among the maternal risk factors for VACTERL studied,
we identified ART, pregestational diabetes, and CLOPD
to be associated with VACTERL. No association was
observed between multiple pregnancy and VACTERL
after correction for ART and birth type. The number of
cases exposed to epilepsy was too low to estimate
reliable ORs.
An important strength of this study is that we per-
formed the largest European case–control study to date
to identify maternal risk factors for VACTERL using clear
diagnostic criteria. Previously, we proposed three differ-
ent VACTERL subtypes: STRICT-VACTERL, VACTERL-
LIKE, and VACTERL-PLUS, as well as a NO-VACTERL
subgroup (van de Putte, van Rooij, et al., 2019). Using
this information, we were able to exclude the NO-
VACTERL cases from our study as they did not fulfill our
diagnostic criteria for VACTERL. This most likely
resulted in a more homogeneous case population com-
pared to other studies with risk estimates that were less
attenuated by nondifferential misclassification. This is
illustrated by the sensitivity analysis in which we
included the NO-VACTERL cases (eTable 2) and showed
risk estimates that were attenuated toward the null value.
Using the remaining three VACTERL subtypes, we also
tried to evaluate etiologic heterogeneity among these sub-
types, but the sample sizes of exposed cases were too
small to draw any meaningful conclusions.
Another strength is the inclusion of a range of sensi-
tivity analyses, in which similar risk estimates were
observed as in the primary analysis. Although some risk
estimates were marginally higher or lower in specific
analyses, they did not change the conclusions of our
study.
A limitation is that no healthy control group was avail-
able, because EUROCAT only registers patients with con-
genital anomalies, genetic syndromes, or chromosomal
abnormalities. A healthy control group is preferable, as
these children do not have any congenital anomalies that
may be caused by maternal risk factors. Previous studies
showed, however, that a control group of patients with
genetic syndromes and chromosomal abnormalities is
comparable to the case group, because of similar recall
errors (Bakker, de Walle, Dequito, van den Berg, & de
Jong-van den Berg, 2007; Lieff, Olshan, Werler, Savitz, &
Mitchell, 1999). In addition, the exposure of such controls
to maternal medication use and smoking was comparable
to the general population of pregnant women (Bakker
et al., 2007; Lieff et al., 1999). Nevertheless, some evidence
indicates that maternal risk factors may be associated with
genetic syndromes as well. Imprinting disorders, for exam-
ple, were associated with ART (Manipalviratn et al., 2009)
and caudal regression syndrome with pregestational diabe-
tes (Garne et al., 2012). However, the numbers of patients
with imprinting disorders or caudal regression syndrome
were low in our control group, and the risk estimates did
not change when controls with imprinting disorders and
caudal regression syndrome were excluded from the spe-
cific analyses (eTable 6) As both the occurrence of several
control disorders and multiple pregnancy, the use of ART,
and chronic maternal illnesses increase with maternal age,
we may not have been able to remove all confounding due
to this factor. With the case mothers being younger on
average, however, residual confounding by maternal age
most likely resulted in underestimation of the effect
estimates.
Another study limitation is the large number of miss-
ing data in some of the variables of interest, as these data
were not collected by all registries. As collecting incom-
plete and inaccurate data are generally a waste of
resources, it is justified for registries to only focus on data
about the fetus/infant and its diagnosis. As the overall
amount of missing data was extensive for body mass
index and maternal education (>85%), we decided not to
include these factors in this study. In addition, we
excluded registries from specific analyses when data on
the risk factor of interest were missing for >50% of the
study population, as this reflects data that are not col-
lected routinely, which could lead to serious selection
bias. After exclusion of specific registries per risk factor
studied, the proportions of missing data were 15–24%,
except for maternal age, birth type, and multiple preg-
nancy (<2%). Multiple imputation of the missing data did
not change our results, however.
Multiple pregnancy was not a risk factor for VAC-
TERL in offspring in our study, after correction for ART
and birth type. In contrast, associations with multiple
pregnancy have been described for birth defects in gen-
eral (Rider, Stevenson, Rinsky, & Feldkamp, 2013), and
for ARM, including ARM with additional congenital
anomalies or VACTERL (Wijers et al., 2013, 2014), non-
syndromic congenital heart defects (Ailes et al., 2014),
and EA (Orford et al., 2000). However, most of these
studies did not include ART in their multivariable
models, whereas ART appeared to influence the risk esti-
mate for multiple pregnancy greatly in this study.
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ART is linked to an increased risk of congenital
anomalies in general (Davies et al., 2012; Hansen, Bower,
Milne, de Klerk, & Kurinczuk, 2005), but also of all indi-
vidual components of VACTERL, along with other car-
diovascular, urogenital, and musculoskeletal anomalies
(Davies et al., 2012; Reefhuis et al., 2009; Wijers
et al., 2013). The possibility of ART being involved in the
etiology of VACTERL was already suggested by case
reports (Kanasugi et al., 2013; Sunagawa et al., 2007). We
showed that couples who conceived via ART had an
increased risk of having a child with VACTERL. This
association could be explained by hypocellularity due to
the use of ART, which may also result in fetal growth
restrictions (Lubinsky, 2017) and decreased birth weight
(Dunietz et al., 2017). However, the question remains
whether this can be attributed to the use of ART or to the
underlying subfertility (Reefhuis et al., 2009; Wijers
et al., 2015).
Prior to our study, the involvement of pregestational dia-
betes in the etiology of VACTERL had only been suggested
by a few case reports (Castori et al., 2008) and one case only
study (Garne et al., 2012). In this case–control study, we
observed that women with pregestational diabetes had an
increased risk of having a child with VACTERL.
Pregestational diabetes, and specifically the corresponding
hyperglycemia, has already been considered a human terato-
gen since the 1980s, when it became evident that it is associ-
ated with increased risks of isolated congenital anomalies
affecting the central nervous system, the skeleton, the kid-
neys, the anorectal area, and the cardiovascular system
(Garne et al., 2012; Liu et al., 2015; Mills, 1982; Wijers
et al., 2014). The mechanism hypothesized for the involve-
ment of pregestational diabetes in the etiology of congenital
anomalies is an overload of glucose in embryonic mitochon-
dria (Akazawa, 2005). Consequently, the production of reac-
tive oxygen species (ROS) is increased, which may lead to
an accumulation of mutations causing increased apoptosis
resulting in congenital anomalies (Akazawa, 2005; Zabihi &
Loeken, 2010). Therefore, it is important that women with
pregestational diabetes achieve proper glycemic control in
the periconceptional period. This was also suggested by Ray
et al., who observed a lower prevalence of congenital anom-
alies among women who received extra preconception care,
compared to women who did not receive care for optimiza-
tion of glycemic control (Ray, O'Brien, & Chan, 2001).
An increased risk of VACTERL was also observed
among mothers who had CLOPD, which were not linked
to VACTERL before. Recently, a paper based on Dutch data
was published on uncontrolled chronic respiratory diseases
as a possible risk factor in the etiology of ARM, an impor-
tant component of VACTERL (van de Putte, de Blaauw,
et al., 2019). The hypothesis was posed that this risk factor
is not specific for ARM, but may disturb embryologic
development in general. Perhaps, this is also true for the eti-
ology of VACTERL. Unfortunately, we were not able to
make the distinction between controlled and uncontrolled
respiratory diseases in the current study.
5 | CONCLUSIONS
In the literature, several genetic risk factors in the etiol-
ogy of the VACTERL association have been identified,
but strong evidence for the involvement of maternal risk
factors is lacking. We identified a role for several mater-
nal risk factors in the etiology of VACTERL, specifically
the use of ART, pregestational diabetes, and CLOPD.
These risk factors have also been identified for several of
the isolated components of VACTERL. This may indicate
that the etiology of VACTERL is not very different from
that of the isolated components. However, it does con-
firm that VACTERL is not solely caused by genetic risk
factors, as we demonstrated a role for multiple maternal
risk factors in the etiology of VACTERL, befitting a mul-
tifactorial etiology.
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